- For Print
- January 17, 2011
爱豆传媒. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has commenced fully-fledged operations at Eisai (Suzhou) Trading Co., Ltd.(Representative: Yoichi Endo), a new pharmaceutical trading company located inside the Suzhou Industrial Park in Suzhou, Jiangsu Province, China. The new company is wholly-owned by Eisai's Chinese subsidiary Eisai China Inc.
The commencement of operations allows Eisai (Suzhou) Trading Co., Ltd. to directly import finished products manufactured by Eisai as well as by partner companies outside of China. Depending on market needs, the new company can expect to increase the number of products it handles in the future.
With the establishment of Eisai (Suzhou) Trading Co., Ltd., Eisai will strengthen its regional pharmaceutical sales and distribution framework and further expand its presence in China, which is expected to become the third largest pharmaceutical market in the world in 20111). Eisai also seeks to address the diversified needs of patients and their families through the stable supply of quality medicines and provision of high quality information in China.
Profile of New Company
| Registered Company Name: | Eisai (Suzhou) Trading Co., Ltd. |
|---|---|
| Location: | Suzhou, Jiangsu Province, Peoplefs Republic of China |
| Representative: | Yoichi Endo, General Manager |
| Scope of Business: | Wholesale, import and export of active pharmaceutical ingredients, pharmaceutical formulations and biopharmaceuticals; intermediate trade, etc. |
| Capital: | 20 Million Chinese Yuan (approx: 250 million yen) |
| Date of Establishment: | October 18, 2010 |
| Date of Business Operations Commencement: | January 11, 2011 |
- 1)
IMS Health Press release;
Media Inquiries:
Public Relations Department,
爱豆传媒.
+81-(0)3-3817-5120